Drugs / SCT800
SCT800
also known as
Recombinant Human Coagulation FVIII · ADVATE · Recombinant Human Coagulation Factor VIII · rFVIII
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02888223 | Sep 2016 → Feb 2017 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT07437404 | Apr 2024 → Dec 2028 expected | hemophilia A | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT03947320 | Dec 2019 → Sep 2020 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04061109 | May 2019 → Mar 2020 | hemophilia A | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03815318 | Jan 2019 → Jan 2020 | hemophilia A | Sinocelltech Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02921945 | Oct 2016 → Dec 2017 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03947567 | Jul 2019 → Apr 2025 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02280265 | Nov 2014 → Dec 2016 | hemophilia A | Nanjing Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05888870 Comparator | Nov 2023 → Dec 2026 expected | hemophilia A | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCT800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02888223 ↗ |
| Known as | ADVATE | “Recombinant Human Coagulation Factor VIII for injection(ADVATE)” NCT02280265 ↗ |
| Known as | Recombinant Human Coagulation Factor VIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02280265 ↗ |
| Known as | Recombinant Human Coagulation FVIII | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03947320 ↗ |
| Known as | rFVIII | “low-dose domestic rFVIII (SCT800) (50IU/kg TIW)” NCT05888870 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Coagulation Factor VIII for injection” NCT02280265 ↗ |
| Route | Intravenous | “Subjects shall receive FVIII intravenous injection treatment” NCT03815318 ↗ |